An investigator initiated phase Ib study assessing motixafortide for patients suffering from acute respiratory distress syndrome (ARDS) secondary to COVID-19 and other respiratory viral infections
Latest Information Update: 03 Dec 2020
At a glance
- Drugs Motixafortide (Primary)
- Indications Adult respiratory distress syndrome; COVID-19 respiratory infection
- Focus Adverse reactions
- 03 Dec 2020 New trial record
- 18 Nov 2020 According to a BioLineRx media release, a preliminary analysis is planned after ten patients have completed the initial treatment period. Based on the preliminary evaluation, a decision to continue or not will be conducted by Dr. Maor, together with the Company.
- 18 Nov 2020 According to a BioLineRx media release, this study will be conducted at Wolfson Medical Center in Holon, Israel, with Dr. Yasmin Maor, Head of the Infectious Disease Unit, as lead investigator. Results from the preliminary analysis is expected in the first half of next year.